Resources

Pioglitazone (Actos) may reduce atherosclerotic plaque inflammation, independent of its glucose-lowering effects….

Edited by Trisha Dunning AM, RN, MEd, PhD, CDE, FRCNA and Glenn Ward MBBS, BSc, DPhil (Oxon), FRACP, FRCPath     Mr. YM was referred by his GP.

This week with Part 2 of our new Incretins series of Homerun Slides, we cover "Incretin Physiology in Type 2 Diabetes Mellitus" and "GLP-1 & GIP Secretion in Type 2 Diabetes Mellitus"….

Introducing … the dLife Healthy, Low Carb Snack List! Snacks can be a double-edged sword for people with diabetes. They may help stave off hunger and overeating, while keeping blood sugar levels from dropping too low. But serious snack attacks can also derail your best efforts to eat healthy and manage …

Bydureon Kit (Not Yet Approved in the US) The new Bydureon once a week GLP-1 may be available in January 2012. Unlike the other currently available GLP-1’s, Bydureon requires reconstitution before its use in a “Connect, Shake, Inject” system. A pen for Bydureon is currently under development. Bydureon is not …

  Men apparently develop type 2 diabetes with less weight gain than women a finding that may help explain why men have higher rates of diabetes in many parts of the world….

All participants showed glycemic improvement but the structured behavioral group showed greater improvements compared to the other two treatment groups.…

Known as Juvisync (Merck), the new medication combines sitagliptin (Januvia, Merck), a dipeptidyl peptidase-4 (DPP-4) inhibitor used for glycemia control, with the cholesterol-lowering simvastatin.…

The investigational weight-loss combination of naltrexone standard release and bupropion standard release (Contrave) reduces the predicted 10-year risk of cardiovascular events, an analysis of four phase III trials showed.…

Even small changes in A1c and BP could significantly reduce the risk of CVD complications in people with type 2 diabetes….